A recent exchange of Letters to the Editor in The Lancet [1,2], has made it evident that the Note for Guidance on "Good Clinical Practice for Trials on Medicinal Products in the European Community" [3], does not provide sufficient advice on the relation between the patient or volunteer on the one hand and the sponsor and his non-physician executive (e.g. monitors) on the other. Although there i...